Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes by Baltussen, R.M. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Avai lable onl ine at www.sc iencedirect .com
journal homepage: www.elsevier .com/ locate / jva l
Value Assessment Frameworks for HTA Agencies: The
Organization of Evidence-Informed Deliberative Processes
Rob Baltussen, PhD*, Maarten Paul Maria Jansen, MSc, Leon Bijlmakers, PhD, Janneke Grutters, PhD,
Anouck Kluytmans, MSc, Rob P. Reuzel, PhD, Marcia Tummers, PhD, Gert Jan van der Wilt, MSc (hon), PhD
Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
A B S T R A C T
Priority setting in health care has been long recognized as an
intrinsically complex and value-laden process. Yet, health technology
assessment agencies (HTAs) presently employ value assessment
frameworks that are ill ﬁtted to capture the range and diversity of
stakeholder values and thereby risk compromising the legitimacy of
their recommendations. We propose “evidence-informed deliberative
processes” as an alternative framework with the aim to enhance this
legitimacy. This framework integrates two increasingly popular and
complementary frameworks for priority setting: multicriteria decision
analysis and accountability for reasonableness. Evidence-informed
deliberative processes are, on one hand, based on early, continued
stakeholder deliberation to learn about the importance of relevant
social values. On the other hand, they are based on rational decision-
making through evidence-informed evaluation of the identiﬁed val-
ues. The framework has important implications for how HTA agencies
should ideally organize their processes. First, HTA agencies should
take the responsibility of organizing stakeholder involvement. Second,
agencies are advised to integrate their assessment and appraisal phases,
allowing for the timely collection of evidence on values that are
considered relevant. Third, HTA agencies should subject their decision-
making criteria to public scrutiny. Fourth, agencies are advised to use a
checklist of potentially relevant criteria and to provide argumentation
for how each criterion affected the recommendation. Fifth, HTA agencies
must publish their argumentation and install options for appeal. The
framework should not be considered a blueprint for HTA agencies but
rather an aspirational goal—agencies can take incremental steps toward
achieving this goal.
Keywords: Health Technology Assessment, Value Assessment
Framework, HTA agency, Evidence-informed deliberative processes.
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Introduction
Priority setting in health care has long been recognized as an
intrinsically complex and value-laden political process that takes
place in an environment of diverging social values and interests
[1–5]. The role of politics in health policy is described as “central
in determining how citizens and policy makers recognize and
deﬁne problems with existing social conditions and policies, in
facilitating certain kinds of public health interventions but not
others, and in generating a variety of challenges in policy
implementation [6].” Indeed, society, including relevant stake-
holders, such as patients, providers, insurers, and citizens, has a
wide range of social values and interests that result in different
perceptions of what makes health interventions valuable [7]. In
such pluralist societies, stakeholders may reasonably disagree on
what values can be used to guide priority setting [4].
However, present value assessment frameworks currently
employed by health technology assessment (HTA) agencies
around the world do not sufﬁciently account for this complex
reality. These frameworks are typically based on the use of
predeﬁned key principles, also labeled “substantive” criteria,
which are believed to reﬂect the most important social values.
This has led HTA agencies to use, for example, “cost-effective-
ness” as an important decision criterion [8].
There is broad recognition that such frameworks are ill ﬁtted
to take into account the wide range and diversity of stakeholder
values and lead to insufﬁcient sets of information [1–3,9]. Ethical
issues in particular are left unaddressed, thereby compromising
the legitimacy of eventual decisions as perceived by stakeholders.
This is illustrated in countries like Brazil, Mexico, and Thailand,
where patients frequently launch court challenges against deci-
sions taken by health authorities [10–12].
We propose an alternative, hybrid value assessment frame-
work for HTA agencies to explicitly address this issue of legiti-
macy. Legitimacy here refers to the reasonableness, or fairness,
of recommendations as perceived by stakeholders, which is an
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important prerequisite for broad societal support for these
recommendations [4]. The framework is based on an integration
of two increasingly popular and complementary frameworks:
multicriteria decision analysis (MCDA) and accountability for
reasonableness (A4R). MCDA evaluates the overall value of
interventions by reference to a set of multiple explicit criteria
[13]; although MCDA is generally praised for its rational pursuit, it
is criticized for being technocratic and lacking a deliberative
component that involves stakeholders [14–16]. A4R recognizes
that stakeholders often justiﬁably disagree about the importance
of speciﬁc social values in setting priorities and argues that
stakeholders are more likely to accept priorities that are the
outcome of a fair process [4,17,18]. The aim of such a process is to
develop a shared basis for decision-making among stakeholders.
A4R has been criticized for being largely theoretical and not
providing guidance on the identiﬁcation and operationalization
of values [14,15,19,20].
“Evidence-informed deliberative processes,” as we name
them, combine the virtues of both A4R and MCDA. They incor-
porate the element of structured decision-making from MCDA
but not the mathematical elements, as we consider the latter to
be only of limited relevance for priority setting. Evidence-
informed deliberative processes are, on the one hand, based on
early, continued deliberation among stakeholders to identify,
reﬂect, and learn about the meaning and importance of relevant
social values. On the other hand, they are based on structured
and rational decision-making—through evidence-informed eval-
uation of the identiﬁed values where possible. Evidence-informed
evaluation allows contributions from stakeholders in terms of
their (clinical) experience and their judgments when stronger
evidence is unavailable [21].
The framework aims to support HTA agencies, at a centralized
or decentralized level, in making reimbursement recommenda-
tions. The framework reﬂects our vision of how HTA agencies
should ideally organize their processes, that is, in such a way that
all stakeholders can confer legitimacy to the recommendations.
This ideal should not be interpreted as a blueprint for HTA
agencies but rather as an aspirational goal—HTA agencies are
advised to take incremental steps toward this goal.
This article ﬁrst describes the key elements of the framework—
stakeholder deliberation to facilitate learning—and then presents
the implications for the conduct of HTA. We use the term “values”
to refer to the preferences of stakeholders and “criteria” to refer to
their more formal operationalization.
Stakeholder Deliberation to Facilitate Learning
The aim of stakeholder involvement in HTA processes is three-
fold. First, it serves to identify the full range of relevant values
that society holds in relation to a particular recommendation and
to ensure relevant evidence collection on these values. Second, it
intends to improve the understanding among stakeholders of
each other’s values. Third, it seeks to achieve maximum coher-
ence among stakeholders in their argumentation regarding a
recommendation [22]. Together, this may lead to an enhanced
sense of legitimacy, in the sense that the recommendation is
considered to be more reasonable. Importantly, the objective of
stakeholder involvement is not necessarily to reach mutual
consensus on a recommendation or to come to a joint decision.
In a democratic society, policymakers hold the ﬁnal authority and
should be held accountable for their ﬁnal decisions.
Value assessment through stakeholder involvement is an
intrinsically complex task. It requires that stakeholders gain, as
much as possible, an in-depth understanding of the health
intervention under scrutiny, including the consequences of its
implementation. In addition, stakeholders need to interpret these
consequences in the context of their own values, other stake-
holders’ values, and widely endorsed public health values, such
as respect for autonomy and nonmaleﬁcence [23]. Stakeholders
are thus required to engage in intellectually demanding moral
reasoning.
Learning among stakeholders is considered essential in this
process and is most likely to occur when stakeholders with
different backgrounds deliberate on a speciﬁc issue [24–26].
Deliberation among stakeholders can facilitate learning by clar-
ifying the different ways in which stakeholders frame policy
problems. By making their underlying assumptions and prefer-
ences explicit, participants may learn from one another and gain
a better understanding of their own position. If confronted with
interpretive frames that are different from their own, stake-
holders may be triggered to reﬂect on their own frames, to verify
their own assumptions, and to partially revise them [25,27].
In this process, evidence is key to inform stakeholders’ under-
standing, and evidence collection should be focused on providing
answers to key questions raised by stakeholders during their
deliberation [7,24,28]. There is anecdotal evidence that deliber-
ation leads to signiﬁcant learning effects in HTA [27,29,30].
However, knowledge of how best to foster learning among stake-
holders is still limited in the ﬁeld of HTA.
Implications for the HTA Process
The use of evidence-informed deliberative processes as value
assessment framework has ﬁve important implications for how
HTA agencies can best organize their processes.
Stakeholders’ Involvement
Relatively little is known about optimal stakeholders involve-
ment in HTA [31–36]. The A4R framework speciﬁes a number of
key conditions for fair processes, including the nature of stake-
holders’ argumentation [4,17,18], but does not provide speciﬁc
guidance. In practice, active stakeholder involvement in HTA can
take different shapes [37,38]. First, stakeholder involvement can
be organized as an exercise independent of HTA agencies
through, for example, round table conferences [29], deliberative
dialogues [39], or interactive technology assessment [7,40]. A
disadvantage of organizing stakeholder involvement independ-
ent of HTA agencies is that it could hamper the uptake of its
ﬁndings by these agencies, and we do not recommend this
approach.
Second, HTA agencies can initiate stakeholder involvement
under their own responsibility. They can commission studies
involving stakeholders deliberation on speciﬁc topics, such as
cochlear implants in The Netherlands [27]. More formally, they
can integrate stakeholder involvement in the various phases of
the HTA process. For example, stakeholders, including the public,
can nominate topics for assessment in Sweden [41]. In the
appraisal phase, stakeholder involvement can be organized
through, for example, granting speaking time during appraisal
committee meetings, as in The Netherlands [42]; organizing a
citizen council, as in the United Kingdom [43]; or soliciting input
and feedback from patients, as in Canada [44] and Scotland [45].
We recommend that HTA agencies take responsibility for
organizing stakeholder involvement, as the agency’s commit-
ment is essential to the political leverage of eventual ﬁndings. As
an important component, we argue that, ideally, an appraisal
committee should include both permanent and temporary stake-
holders. Permanent members should be installed to endorse the
broad public interest and take the responsibility of developing
recommendations on the basis of the deliberative process.
Temporary members should be included to represent speciﬁc
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stakeholders, including their interests and expertise, with their
appointment dependent on the recommendation under scrutiny.
HTA agencies are advised to take incremental steps toward
this ideal.
Integration of Assessment and Appraisal Phases
HTA agencies typically separate the assessment from the
appraisal phase in the HTA process. The assessment phase
involves the collection of evidence of a standard set of criteria,
pushing the consideration of further criteria into the appraisal
phase. However, this often leaves an appraisal committee with
incomplete evidence upon which to base their recommendation.
We argue that the assessment and appraisal phases should be
integrated, in the sense that the relevant considerations should
be explored from the outset—this would then allow the timely
collection of evidence on these aspects and their inclusion in the
appraisal of the health intervention. The Netherlands is now
introducing an early scoping exercise in its HTA process, in which
stakeholders are consulted to determine relevant outcome meas-
ures for the effectiveness of an intervention [46].
Ideally, HTA should be organized as an iterative learning
process, which allows the ongoing identiﬁcation of values and
collection of evidence on associated criteria throughout the
process. This may require an expansion of the present, strict
time frames that HTA agencies have for the development of
recommendations. If such an expansion is not possible, we
instead recommend HTA agencies to intensify their decision-
making process.
Speciﬁcation of Criteria
Priority setting may involve a wide range of criteria, as repeatedly
demonstrated in international surveys [47], decision frameworks
[48–50], and guidelines [49]. Among this wide range, many HTA
agencies consistently use a number of explicit criteria for the
evaluation of every intervention. For example, “safety,” “effec-
tiveness,” “cost-effectiveness,” “severity of disease,” and “budget
impact” are often considered as such by HTA agencies [51–53]. We
label these criteria as “generic criteria.” At the same time, more
“contextual” criteria appear to be used for speciﬁc interventions
only, and these include many considerations (e.g., “responsibility
for own health” for interventions targeting behavior-related
diseases, such as smoking, or “size of the population affected”
for interventions targeting orphan diseases).
The use of “generic” criteria in particular give the impression
of being politically sanctioned and therefore justiﬁed. In reality,
however, they are often the manifestation of how HTA agencies
(attempt to) specify the more abstract and fundamental politi-
cally ratiﬁed values in a country [22]. This speciﬁcation by HTA
agencies, typically lacking proper stakeholder participation, risks
compromising the legitimacy of this use of standard criteria and
any forthcoming recommendations. HTA agencies should subject
their decision-making criteria to public scrutiny by means of a
democratic process [54]. In doing so, HTA agencies may learn
from other countries in terms of how to organize this democratic
process and/or specify their criteria.
Development of Recommendations
The criteria that are identiﬁed throughout the process likely
require further assessment. This may take the shape of generat-
ing an evidence base for criteria that are quantiﬁable—for
example, an intervention’s performance on the criterion “cost-
effectiveness” can be assessed quantitatively by means of cost-
effectiveness analysis [55–57]. Criteria that are nonquantiﬁable
may be subjected to qualitative analysis (e.g., ethical analysis or
[expert] stakeholder opinions). These pieces of quantitative and
qualitative information are inputs into the deliberative process.
HTA agencies are advised to develop a checklist, including their
range of identiﬁed and speciﬁed criteria. They can use this
checklist to verify whether these criteria are relevant to particular
recommendations in order not to overlook criteria.
For every criterion, the appraisal committee should argue
whether and how it affects the recommendation (in a positive
or negative way). The committee must eventually come to a ﬁnal
recommendation, thereby providing argumentation for which
criteria are considered to be of overriding importance. We stress
that this process should not be considered as a one-time exercise
but, ideally, as an iterative learning process in the committee—of
course, within the time frame of the HTA agencies. Also, we
stress the importance of deliberation in dealing with the full
range of criteria and wish to emphasize that, in our view,
quantitative decision aids can never fully replace the force of
argumentation [58].
An important issue in stakeholder involvement in formal HTA
processes is that of vested interests, wherein stakeholders (ini-
tially) plead in favor of their own interests. As such, stakeholder
involvement in the presence of vested interests likely captures
private values, but it is less able to capture public interests that
countries may rightfully choose to endorse, such as safeguard-
ing equal access to good quality health care, efﬁciency, and cost
containment. These public interests are not typically acknowl-
edged as important by individual stakeholders. As noted
earlier, we advise HTA agencies to install permanent members
in the appraisal committee, being stakeholders representing
public interests. In the appraisal process, all argumentation
that is tabled must be subjected to deliberation and, in the end,
balanced against each other. The permanent members have
the responsibility to develop recommendations on the basis of
this process, and the ﬁnal decision rests with the accountable
policymaker.
The task of HTA agencies is not restricted to development of
strictly positive or negative recommendations. The above process
may lead to recommendations for price negotiation or the
collection of further evidence. Together with stakeholders, agen-
cies may also identify alternative ways of implementing inter-
ventions, which may optimize their value.
Communication and Appeal
In a democratic society, policymakers hold the authority to make
decisions and are accountable for the decision-making process. It
is, therefore, important that HTA agencies communicate all
argumentation to justify the recommendation on the use (or
rejection) of criteria. Doing so in accountable ways will increase
the likelihood that stakeholders, including citizens who did not
participate [4,7]—and did not go through a learning process—can
understand and accept the reasoning underlying the ﬁnal
decision.
In addition, societal perceptions of what should count as
legitimate arguments for recommendations are subject to change
over time or as new evidence becomes available. Health author-
ities should, therefore, organize an appeal mechanism—or at
least be receptive to new input and arguments that were initially
not taken into account [1,4].
Discussion
This article presents evidence-informed deliberative processes as
a hybrid value assessment framework that integrates the virtues
of A4R (i.e., the deliberation among stakeholders to incorporate
relevant social values) and MCDA (i.e., structured and rational
decision-making informed by evidence on multiple criteria). The
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framework includes various elements that are frequently men-
tioned in the HTA literature (e.g., involving stakeholders), ensur-
ing that all potentially relevant criteria are considered and
explaining the reasoning for recommendations.
These are now, for the ﬁrst time, being presented in a unifying
framework and translated into practical guidance for HTA agen-
cies. Adopting evidence-informed deliberative processes as a
value assessment framework could be an important step forward
for HTA agencies in optimizing the legitimacy of their priority-
setting decisions.
To achieve this, HTA agencies can probably best incorporate
elements of the framework incrementally, adjusting them to
local needs and affordances. For example, HTA agencies may
decide to include scoping exercises with stakeholders on the
relevant contextual criteria for a speciﬁc decision, organize
deliberative dialogues, or decide to publish their argumentation
vis-à-vis their recommendations. Again, evidence-informed,
deliberative processes should by no means be considered a
blueprint for HTA agencies—they should, rather, be considered
an aspirational goal, and HTA agencies can implement compo-
nents to progress toward that goal. We are now undertaking
research activities under the heading of the REVISE2020 project to
develop practical guidance for HTA agencies. This will take the
shape of a menu of options that HTA agencies can consider to
improve the legitimacy of their decision-making process [59].
Evidence-informed deliberative processes require the collec-
tion and/or development of evidence on all identiﬁed values
where possible, supplemented with experiences and judgments
where relevant. The interpretation of this information may be
challenging in terms of the great uncertainties involved. Yet, we
see this challenge as merely reinforcing the need to deliberate on
these values as informed by available evidence, rather than
ignoring it altogether.
We recommend that HTA agencies use a comprehensive
checklist of criteria that may be relevant in particular contexts,
including their range of identiﬁed and speciﬁed criteria. Yet, one
may question whether a good deliberative process would not lead
to the consideration of the same values and to the same
recommendation. We believe that, as the development of such
processes is in its infancy, the use of a checklist may still be
useful to avoid overlooking certain criteria.
On a more methodological note, evidence-informed delib-
erative processes can also be considered a general heading for
various HTA approaches that are based on the same principles
of stakeholder deliberation and evidence gathering, for exam-
ple, program budgeting and marginal analysis [60] and choos-
ing health plans all together [61]. These approaches share
the same challenges in their processes, such as avoidance of
stakeholder dominance. Shared research activities can inform
the optimal form and implementation of evidence-informed
deliberative processes, per decision context. The ﬁelds of
general policy and technology assessment [24], political scien-
ces, and governance studies [62,63] can provide important
lessons.
Ideally, evidence-informed deliberative processes are also
applied in the early phase of the development of interventions,
to take into account stakeholder values vis-à-vis medical inno-
vations. In the early phase, this inclusion offers great opportunity
to better steer the practice of medical innovation toward high-
value interventions, to more efﬁciently collect relevant evidence,
and to avoid the implementation of low-value interventions [64].
Yet, to our knowledge, this has rarely been applied.
Finally, as countries around the world face challenges regard-
ing the sustainability of their health systems, driven by medical
innovations, growing needs of aging populations, and higher
public expectations [65], they will be increasingly confronted
with the need to make difﬁcult choices. We see the develop-
ment of evidence-informed deliberative processes as a suitable
response and a necessary condition to safeguard societal support
for the choices that are made.
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